Get the Stockscreener App
26.46
2.88%
0.74
After Hours:
26.60
0.14
+0.53%
Ultragenyx Pharmaceutical Inc stock is traded at $26.46, with a volume of 3.81M.
It is up +2.88% in the last 24 hours and down -1.64% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
See More
Previous Close:
$25.72
Open:
$26.25
24h Volume:
3.81M
Relative Volume:
1.68
Market Cap:
$2.61B
Revenue:
$669.43M
Net Income/Loss:
$-609.36M
P/E Ratio:
-4.3334
EPS:
-6.1061
Net Cash Flow:
$-507.20M
1W Performance:
+3.81%
1M Performance:
-1.64%
6M Performance:
+15.50%
1Y Performance:
-9.60%
1-Day Range:
$26.00
$26.91
1-Week Range:
$25.04
$28.50
52-Week Range:
$18.29
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
26.46 | 2.50B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy - Stocktwits
Ultragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade) - Seeking Alpha
RARE Maintained by Morgan Stanley -- Price Target Raised to $74 - GuruFocus
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Morgan Stanley Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
How Investors May Respond To Ultragenyx Pharmaceutical (RARE) First FDA Accelerated Approval For GENGLYCOS - simplywall.st
182,638 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Blue Owl Capital Holdings LP - MarketBeat
RTW INVESTMENTS, LP Buys Ultragenyx Pharmaceutical Inc (RARE) -- Shares Look 44% Undervalued on GF Value - GuruFocus
RARE Maintained by Canaccord Genuity -- Price Target Raised to $83 - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx scores FDA approval for gene therapy made at Bedford facility - The Business Journals
RARE Maintained by Citigroup -- Price Target Raised to $58.00 - GuruFocus
Citigroup Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease - MedCity News
Ultragenyx Shares Surge as FDA Grants First-Ever Approval for GSDIa Gene Therapy - finance.biggo.com
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing - PharmTech.com
RARE Maintained by Wells Fargo -- Price Target Raised to $46.00 - GuruFocus
Ultragenyx, after setbacks, nabs first gene therapy approval - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $46.00 Price Target at Wells Fargo & Company - MarketBeat
FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia - BioPharm International
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Analyst Upgrade - MarketBeat
Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa - pharmaphorum
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos - TradingView
Ultragenyx Lands Genglycos Approval And Sets Its Sights On A PRV Double - insights.citeline.com
Ultragenyx's new therapy targets patients with a rare genetic disease. It costs $2.7 million. - The Business Journals
H.C. Wainwright reiterates Ultragenyx stock rating at buy By Investing.com - Investing.com Nigeria
FDA approves Ultragenyx gene therapy - STAT
Canaccord raises Ultragenyx stock price target on FDA approval By Investing.com - Investing.com South Africa
Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock - Yahoo Finance
Ultragenyx Nabs FDA Nod for First Gene TherapyUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating at buy - Investing.com
Canaccord raises Ultragenyx stock price target on FDA approval - Investing.com
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy - Pharmaceutical Business review -
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy - MarketBeat
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $103 - GuruFocus
Ultragenyx’ Genglycos wins FDA accelerated approval - The Pharma Letter
FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia - AllSci
Eagle Health Investments LP Acquires Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx stock surges on FDA gene therapy approval - Investing.com
Ultragenyx’s gene therapy wins first FDA approval for rare metabolic disorder - 101 WIXX
Ultragenyx Earnings Call Signals Record Sales, 2027 Pivot - TipRanks
Ultragenyx gets its first gene therapy over the regulatory finish line - FirstWord Pharma
RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher - Stocktwits
Ultragenyx receives FDA approval for gene therapy treating GSDIa By Investing.com - Investing.com Nigeria
Form 8K Ultragenyx For: 19 August By Investing.com - Investing.com South Africa
Ultragenyx stock surges on FDA gene therapy approval By Investing.com - Investing.com Australia
Ultragenyx’s gene therapy for rare metabolic disorder secures US FDA nod - 1470 & 100.3 WMBD
RARE Looks 41.8% Undervalued on GF Value™ After FDA Approval Boo - GuruFocus
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):